A highly decreased binding of cyclic adenosine monophosphate to protein kinase A in erythrocyte membranes is specific for active psoriasis

Journal of Investigative Dermatology

Volumn 119, Issue 1, 2002, Pages 160-165

  Schopf, Rudolf E ^a   Langendorf, Yvonne ^a   Benz, Roman E ^a   Färber, Lothar ^b   Benes, Peter ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Clinical Research and Development   (Germany)

Author keywords

Anthralin; Cyclosporine A; Dermatitis; Etretinate; Psoriasis Area and Severity Index

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOSPORIN A; DITHRANOL; ETRETINATE;

ADULT; AGED; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ECZEMA; ERYSIPELAS; ERYTHEMA NODOSUM; ERYTHROCYTE MEMBRANE; ERYTHRODERMA; HOSPITALIZATION; HUMAN; HUMAN TISSUE; LICHEN PLANUS; NECROTIZING ARTERITIS; PRIORITY JOURNAL; PROTEIN BINDING; PSORIASIS; PSORIASIS VULGARIS; RANK SUM TEST; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TINEA; TRANSIENT ACANTHOLYTIC DERMATOSIS; URTICARIA;

EID: 0036421805     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2002.01808.x     Document Type: Article

References (37)

1. Adachi K, Iiszuka H, Halprin KM, Levine V: Epidermal cyclic AMP is not decreased in psoriasis lesions. J Invest Dermatol 74:74-76, 1980
2. Alessandrini F, Stachowitz S, Ring J, Behrendt H: The level of prosaposin is decreased in the skin of patients with psoriasis vulgaris. J Invest Dermatol 116:394-400, 2001
3. Brion DE, Raynaud F, Plet A, Laurent P, Leduc B, Anderson W: Deficiency of cyclic AMP-dependent protein kinases in human psoriasis. Proc Natl Acad Sci USA 83:5272-5276, 1986
4. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial. Lancet 357:1842-1847, 2001
5. Czernielewski J, Schalla W, Desbas C, Brun P: Beta-blockers induce class II MHC antigens on psoriatic keratinocytes. Lancet i:808, 1986
6. Dimon-Gadal S, Gerbaud P, Thérond P, Guibourdenche J, Anderson WB, Evain-Brion D, Raynaud F: Increased oxidative damage to fibroblasts in skin with and without lesions in psoriasis. J Invest Dermatol 114:984-978, 2000
7. Dohrman DP, Diamond I, Gordon AS: Ethanol causes translocation of cAMP-dependent protein kinase catalytic subunit to the nucleus. Proc Natl Acad Sci USA 93:10217-10221, 1996
8. Dreyfuss G, Schwartz KJ, Blout ER: Compartmentalization of cyclic AMP-dependent protein kinases in human erythrocytes. Proc Natl Acad Sci USA 75:5926-5930, 1978
9. Eedy DJ, Canavan JP, Shaw C, Trimble ER: Beta-adrenergic stimulation of cyclic AMP is defective in cultured dermal fibroblasts of psoriatic subjects. Br J Dermatol 122:477-483, 1990
10. Fredricksson T, Petterson U: Severe psoriasis-Oral therapy with a new retinoid. Dermatologica 157:238-244, 1978
11. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1:442-447, 1995
12. Greaves MW, Weinstein GD: Treatment of psoriasis. N Engl J Med 332:581-588, 1995
13. Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N, Cronstein BN: Inflammatory cytokines regulate functions and expression of adenosine A (2A) receptors in human monocytic THP-1 cells. J Immunol 167:4026-4032, 2001
14. Kumar R, Weiss VS, West DP, Chiero LA: Erythrocyte membrane phosphorylation in untreated and in etretinate-treated psoriatic patients. Br J Dermatol 109:277-286, 1983
15. Liapi C, Takahashi N, Raynaud F, Evain-Brion D, Anderson WB: Effects of [D-Ala1] peptide T-NH2 and HIV envelope glycoprotein gp 120 on cyclic AMP dependent protein kinases in normal and psoriatic human fibroblasts. J Invest Dermatol 110:332-327, 1998
16. Morsches B, Benes P, Holzmann H, Henrich B: Penetration kinetics of dehydroepiandrosterone through the erythrocyte membrane. Arch Dermatol Res 270:49-55, 1981
17. Nemoto O, Takeda J, Adachi K, Halprin KM, Woodyard CW, Levine V: Reversal of beta-agonist-induced refractoriness in skin by tetracaine and mepacrine. J Invest Dermatol 80:237-240, 1983
18. Nickoloff BJ, Karabin GD, Barker JN, et al: Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138:129-140, 1991
19. Partsch G, Gatzakis S, Eberl R, Luger A: Der Purin-Wiederverwertungsstoffwechsel in Erythrozyten von Psoriatikern (the Purine Salvage Pathway in Psoriatic Erythrocytes). Zeitschrift für Hautkrankheiten. Berlin: Grosse Verlag 54: 1979: pp 808-812
20. Raynaud R, Leduc C, Anderson WB, Evain-Brion D: Retinoid treatment of human psoriatic fibroblasts induces an increase in cyclic AMP-dependent protein kinase activity. J Invest Dermatol 89:105-110, 1987
21. Raynaud F, Gerbaud P, Enjolras O, Gorin I, Donnadieu M, Anderson WB, Evain-Brion D: A cAMP abnormality in psoriasis. Lancet i:1153-1156, 1989
22. Raynaud F, Gerbaud P, Bouloc A, Gorin I, Anderson WB, Evain-Brion D: Rapid effect of treatment of psoriatic erythrocytes with the synthetic retinoid acitretin to increase 8-azido cyclic AMP binding to the RI regulatory subunit. J Invest Dermatol 100:77-81, 1993
23. Raynaud F, Evain-Brion D, Gerbaud P, Marciano D, Gorin I, Liapi C, Anderson WB: Oxidative modulation of cyclic AMP-dependent protein kinase in human fibroblasts: Possible role in psoriasis. Free Radic Biol Med 22:623-632, 1997
24. Schopf RE, Straussfeld E: Stimulus-dependent increased generation oxygen intermediates in monocytes and polymorphonuclear leukocytes in psoriasis. J Invest Dermatol 84:73-76, 1985
25. Schopf RE, Müller F-J, Benes P, Morsches B: Augmented glucose-6-phosphate dehydrogenase activity and normal penetration and metabolism of dehydroepiandrosterone in mononuclear leukocytes in psoriasis. Arch Dermatol Res 278:393-397, 1986
26. Schopf RE, Hücher J, Rehder M, Müller F-J, Morsches B: Etretinate of cyclosporin-A treatment normalizes the enhanced respiratory burst of polymorphonuclear leukocytes in psoriasis. Arch Dermatol Res 284:227-231, 1992
27. Schopf RE, Aust H, Knop J: Treatment of psoriasis with the mouse-human chimeric monoclonal antibody against TNF-alpha, infliximab. J Am Acad Dermatol, in press
28. Semplicini A, Mozzato MG, Rigon E, et al: Red blood cell sodium and potassium fluxes in psoriatic patients. Eur J Clin Invest 18:47-51, 1988
29. Thérond P, Gerbaud P, Dimon S, Anderson WB, Evain-Brion D, Raynaud F: Antioxidant enzymes in psoriatic fibroblasts and erythrocytes. J Invest Dermatol 106:1325-1328, 1996
30. Tournier S, Gerbaud P, Anderson WB, Lohmann SM, Evain-Brion D, Raynaud F: Post-translational abnormality of the type II cyclic AMP-dependent protein kinase in psoriasis: Modulation by retinoic acid. J Cell Biochem 57:647-654, 1995
31. Tournier S, Raynaud F, Gerbaud P, Lohmann SM, Anderson WB, Evain-Brion D: Retinoylation of the type II cAMP-binding regulatory subunit of cAMP. J Cell Physiol 167:196-203, 1996
32. Voorhees JJ, Duell EA: Psoriasis as a possible defect of the adenyl cyclase-cyclic AMP cascade. Arch Dermatol 104:352-358, 1971
33. Voorhees JJ, Duell EA, Bass LJ, Powell JA, Harrell JA: Decreased cyclic AMP in the epidermis of lesions of psoriasis. Arch Dermatol 105:695-701, 1972a
34. Voorhees JJ, Duell EA, Bass LJ, Powell JA, Harrell JA: The cyclic AMP system in normal and psoriatic epidermis. J Invest Dermatol 59:114-120, 1972b
35. Voorhees JJ, Marcelo CL, Duell EA: Cyclic AMP, cyclic GMP, and glucocorticoids as potential metabolic regulators of epidermal proliferation and differentiation. J Invest Dermatol 65:179-190, 1975
36. Walter U, Uno I, Liu AY-C, Greengard P: Identification, characterization, and quantitative measurement of cyclic AMP receptor proteins in cytosol of various tissues using a photoaffinity ligand. J Biol Chem 252:6494-6500, 1977
37. Yoshikawa K, Adachi K, Halprin KM, Levine V: On the lack of response to catecholamine stimulation by the adenyl cyclase system in psoriatic lesions. Br J Dermatol 92:619-624, 1975